Repligen (NASDAQ:RGEN) Rating Increased to Buy at Wall Street Zen

Key Points

• Repligen has been upgraded from a "hold" rating to a "buy" rating by Wall Street Zen, indicating increased investor confidence in the company's prospects.
• Institutional investors hold 97.64% of Repligen's stock, reflecting strong institutional interest and investment in the company.
• The company's most recent earnings report showed a 14.8% year-over-year increase in revenue, although earnings per share fell short of analyst expectations.

Repligen (NASDAQ:RGEN - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently commented on RGEN. Hsbc Global Res upgraded Repligen to a "strong-buy" rating in a research note on Wednesday, October 1st. Weiss Ratings restated a "sell (d)" rating on shares of Repligen in a research note on Wednesday. Wells Fargo & Company cut their target price on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 30th. Barclays boosted their target price on Repligen from $150.00 to $160.00 and gave the company an "overweight" rating in a research note on Thursday, October 2nd. Finally, HC Wainwright restated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Wednesday, September 3rd. One investment analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $169.62.

Repligen Stock Performance

Shares of RGEN stock opened at $145.24 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The stock has a market cap of $8.17 billion, a PE ratio of -580.94, a price-to-earnings-growth ratio of 2.74 and a beta of 1.08. The stock has a 50-day moving average of $125.12 and a 200-day moving average of $125.72. Repligen has a one year low of $102.96 and a one year high of $182.52.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. The business had revenue of $182.37 million for the quarter, compared to the consensus estimate of $174.62 million. During the same quarter last year, the firm earned $0.40 EPS. The company's revenue for the quarter was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, sell-side analysts expect that Repligen will post 1.72 earnings per share for the current year.

Insiders Place Their Bets

In other Repligen news, Director Martin D. Madaus purchased 1,800 shares of the company's stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average price of $112.13 per share, for a total transaction of $201,834.00. Following the purchase, the director owned 1,800 shares in the company, valued at approximately $201,834. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 1.20% of the company's stock.

Institutional Investors Weigh In On Repligen

A number of large investors have recently added to or reduced their stakes in RGEN. Price T Rowe Associates Inc. MD raised its stake in Repligen by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company's stock valued at $962,711,000 after acquiring an additional 430,039 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its stake in Repligen by 3,219.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 413,425 shares of the biotechnology company's stock valued at $51,422,000 after acquiring an additional 400,970 shares during the period. Geneva Capital Management LLC increased its position in Repligen by 239.6% during the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company's stock worth $60,639,000 after buying an additional 343,991 shares during the period. Blue Whale Capital LLP acquired a new stake in shares of Repligen during the second quarter worth $35,782,000. Finally, Nuveen LLC bought a new stake in shares of Repligen in the first quarter valued at about $35,536,000. Institutional investors own 97.64% of the company's stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.